Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 157 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vitamin A tracer Clear all
Completed Early Phase 1 Interventional

Chelation Therapy in Diabetic Patients With Critical Limb Ischemia

NCT03424746
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Arterial Disease
Interventions
disodium EDTA
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
50 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 25, 2026, 10:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Assessment of DHA On Reducing Early Preterm Birth

NCT02626299
View directory record Official record
Conditions
Preterm Birth
Interventions
Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 25, 2026, 10:23 AM EDT
Recruiting Phase 2 Interventional

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428
View directory record Official record
Conditions
Carcinoma, Non-small-Cell Lung
Interventions
Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC), Low Molecular Weight Heparin (LMWH)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
26
States / cities
La Jolla, California • Orange, California • Stanford, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 25, 2026, 10:23 AM EDT
Completed Phase 1 Interventional

Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

NCT00554827
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma
Interventions
Vitamin B12, Folic Acid, Pralatrexate
Dietary Supplement · Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
10
States / cities
Duarte, California • Redwood City, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Sep 25, 2026, 10:23 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Efficacy of Four Supplements on Improving Readiness for Intimacy

NCT05862519
View directory record Official record
Conditions
Libido, Intimacy, Gastrointestinal Issues
Interventions
Reset, Stay Ready Fiber, Libido, Testosterone supplement
Dietary Supplement
Lead sponsor
906 CMVI Holdings
Industry
Eligibility
18 Years to 44 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 25, 2026, 10:23 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

NCT05680818
View directory record Official record
Conditions
Autosomal Dominant Hypocalcemia (ADH)
Interventions
Encaleret, Standard of Care
Drug · Dietary Supplement
Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Industry
Eligibility
16 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
11
States / cities
Oakland, California • Aurora, Colorado • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 25, 2026, 10:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dairy Fat as a Mediator of Vitamin E Adequacy in Individuals With Metabolic Syndrome

NCT01787591
View directory record Official record
Conditions
Non-alcoholic Fatty Liver, Metabolic Syndrome
Interventions
Fat-Free Milk, Low-Fat Milk, Full-Fat Milk, Soy Milk
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 25, 2026, 10:23 AM EDT
Terminated Phase 2Phase 3 Interventional

Vitamin B12 Status and Response to Vitamin B12 Supplementation in Patients With Parkinson's Disease

NCT00208611
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Vitamin B12 Supplementation
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
21 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Sep 25, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study in Healthy Subjects

NCT00924911
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Sep 25, 2026, 10:23 AM EDT
Completed Phase 1 Interventional

ATRA, Celecoxib, and Itraconazole as Maintenance

NCT02401295
View directory record Official record
Conditions
Relapsed Multiple Myeloma
Interventions
ATRA, Celecoxib, Itraconazole
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 25, 2026, 10:23 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

NCT02712905
View directory record Official record
Conditions
Solid Tumors and Hematologic Malignancy
Interventions
INCB059872, all-trans retinoic acid (ATRA), azacitidine, nivolumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 25, 2026, 10:23 AM EDT
Completed Phase 1 Interventional

Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)

NCT00792857
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions
CTAP201 Injection, Doxercalciferol
Drug
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Peoria, Arizona • Springfield, Massachusetts • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2014 · Synced Sep 25, 2026, 10:23 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction

NCT00532844
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Sapropterin Dihydrochloride, Sapropterin Dihydrochloride and Vitamin C
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 25, 2026, 10:23 AM EDT
Completed Phase 1 Interventional

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

NCT01134341
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma
Interventions
Pralatrexate Injection, Bexarotene Capsules, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Stanford, California • New York, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 25, 2026, 10:23 AM EDT
Completed Phase 4 Interventional Results available

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

NCT02464969
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban, Standard of Care
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
0 Days to 17 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
84
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 25, 2026, 10:23 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis

NCT02859896
View directory record Official record
Conditions
Secondary Hyperparathyroidism-Chronic Kidney Disease
Interventions
Doxercalciferol (GZ427397), Calcitriol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
5 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 25, 2026, 10:23 AM EDT
Completed Phase 1 Interventional

Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)

NCT02227459
View directory record Official record
Conditions
Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)
Interventions
ND-L02-s0201 Injection
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 25, 2026, 10:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Micronutrients to Prevent Noise-induced Hearing Loss

NCT00808470
View directory record Official record
Conditions
Noise-Induced Hearing Loss
Interventions
beta-carotene, vitamins C and E, magnesium, Placebo
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 35 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Sep 25, 2026, 10:23 AM EDT
Terminated No phase listed Observational

Post Market Study of the 3DKnee™ With E-plus Insert

NCT01551472
View directory record Official record
Conditions
Degenerative Joint Disease, Osteoarthritis, Traumatic Arthritis
Interventions
3DKnee™ System with Vitamin E UHMWPE Tibial Inserts
Device
Lead sponsor
Encore Medical, L.P.
Industry
Eligibility
40 Years to 75 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
6
States / cities
Burbank, California • Oceanside, California • Fort Myers, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 25, 2026, 10:23 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

NCT03358706
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg, Warfarin 10 mg, Vitamin K 10 mg, Omeprazole 20 mg, Dextromethorphan 30 mg, Caffeine 100 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Cypress, California • Miami Springs, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Sep 25, 2026, 10:23 AM EDT
Completed Not applicable Interventional

A Collection of Case Studies in Infants With UCD to Evaluate Infant Growth and the Safety of a New Medical Food for UCD

NCT03911089
View directory record Official record
Conditions
Urea Cycle Disorder, Inborn Errors of Metabolism
Interventions
UCD Anamix Infant
Other
Lead sponsor
Nutricia Research
Industry
Eligibility
Up to 30 Days
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Sep 25, 2026, 10:23 AM EDT
Withdrawn Phase 1 Interventional

PDT Plus Vitamin D3 for Anal Dysplasia

NCT02698293
View directory record Official record
Conditions
Anal Dysplasia, Carcinoma in Situ
Interventions
Gliolan, Vitamin D3 cholecalciferol), Photodynamic Therpay
Drug · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 25, 2026, 10:23 AM EDT
Completed Phase 3 Interventional

SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism

NCT00062803
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
SR34006, (LMW)heparin, Warfarin VKA, Acenocoumarol VKA
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
54
States / cities
Loma Linda, California • San Diego, California • Aurora, Colorado + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2009 · Synced Sep 25, 2026, 10:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

DAYLIGHT: Vitamin D Therapy in Individuals at High Risk of Hypertension

NCT01240512
View directory record Official record
Conditions
Hypertension, Vitamin D Deficiency, Pre-Hypertension
Interventions
Cholecalciferol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
3
States / cities
Hartford, Connecticut • Boston, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 25, 2026, 10:23 AM EDT